Sitaxsentan-13C6

Sitaxsentan-13C6 (IPI 1040-13C6) is 13C labeled Sitaxsentan (HY-76520) . Sitaxsentan (IPI 1040; TBC-11251) is a selective endothelin A (ETA) receptor antagonist.

Product Specifications

Product Name Alternative

IPI 1040-13C6; TBC-11251-13C6

UNSPSC

12352005

Target

Endothelin Receptor; Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cardiovascular Disease; Endocrinology

Smiles

O=S(C1=C(C(C[13C]2=[13C][13C]3=[13C]([13C]=[13C]2C)OCO3)=O)SC=C1)(NC4=C(C(C)=NO4)Cl)=O

Molecular Formula

C12 13C6H13ClN2O6S2

Molecular Weight

458.84

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Chin M, Levy RD, Yoshida EM, Byrne MF.Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.Can Respir J. 2012 Jan-Feb;19 (1) :e1-2.|[3]Sandoval J, et al. STRIDE-4 investigators.Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.Pulm Pharmacol Ther. 2012 Feb;25 (1) :33-9. Epub 2011 Nov 2.|[4]Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.Vasc Health Risk Manag. 2011;7:119-24. Epub 2011 Mar 2.|[5]Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.Am J Physiol Heart Circ Physiol. 2010 Oct;299 (4) :H1118-23. Epub 2010 Aug 6.|[6]Kaehler, et al. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wien Klin Wochenschr. 2011 Apr;123 (7-8) :248-52. Epub 2011 Mar 31.